{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:01:49Z","timestamp":1784595709486,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1186\/1471-2202-9-s3-s6","type":"journal-article","created":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T19:12:45Z","timestamp":1228936365000},"source":"Crossref","is-referenced-by-count":17,"title":["Intranasal administration of acetylcholinesterase inhibitors"],"prefix":"10.1186","volume":"9","author":[{"given":"Henry R","family":"Costantino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis Kays","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C","family":"Quay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,10]]},"reference":[{"key":"1003_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","volume":"337","author":"HR Costantino","year":"2007","unstructured":"Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC: Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm. 2007, 337: 1-24. 10.1016\/j.ijpharm.2007.03.025.","journal-title":"Int J Pharm"},{"key":"1003_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/(SICI)1099-081X(199812)19:9<571::AID-BDD142>3.0.CO;2-O","volume":"19","author":"Y Wang","year":"1998","unstructured":"Wang Y, Aun R, Tse FL: Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos. 1998, 19: 571-575. 10.1002\/(SICI)1099-081X(199812)19:9<571::AID-BDD142>3.0.CO;2-O.","journal-title":"Biopharm Drug Dispos"},{"key":"1003_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1021\/js9900295","volume":"88","author":"HS Chow","year":"1999","unstructured":"Chow HS, Chen Z, Matsuura GT: Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci. 1999, 88: 754-758. 10.1021\/js9900295.","journal-title":"J Pharm Sci"},{"key":"1003_CR4","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/jps.1122","volume":"90","author":"HH Chow","year":"2001","unstructured":"Chow HH, Anavy N, Villalobos A: Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. J Pharm Sci. 2001, 90: 1729-1735. 10.1002\/jps.1122.","journal-title":"J Pharm Sci"},{"key":"1003_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0022-510X(01)00532-9","volume":"187","author":"XF Liu","year":"2001","unstructured":"Liu XF, Fawcett JR, Throne RG, DeFor TA, Frey WH: Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci. 2001, 187: 91-97. 10.1016\/S0022-510X(01)00532-9.","journal-title":"J Neurol Sci"},{"key":"1003_CR6","first-page":"522","volume":"25","author":"QZ Zhang","year":"2004","unstructured":"Zhang QZ, Jiang XG, Wu CH: Distribution of nimodipine in brain following intranasal administration in rats. Acta Pharmacol Sin. 2004, 25: 522-527.","journal-title":"Acta Pharmacol Sin"},{"key":"1003_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ejps.2005.01.009","volume":"24","author":"U Westin","year":"2005","unstructured":"Westin U, Piras E, Jansson B, Bergstrom U, Dahlin M, Brittebo E, Bjork E: Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci. 2005, 24: 565-573. 10.1016\/j.ejps.2005.01.009.","journal-title":"Eur J Pharm Sci"},{"key":"1003_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11095-006-9534-z","volume":"23","author":"UE Westin","year":"2006","unstructured":"Westin UE, Bostrom E, Grasjo J, Hammarlund-Udenaes M, Bjork E: Direct nose-to-brain transfer of morphine after nasal administration to rats. Pharm Res. 2006, 23: 565-572. 10.1007\/s11095-006-9534-z.","journal-title":"Pharm Res"},{"key":"1003_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00280-005-0018-3","volume":"57","author":"D Wang","year":"2006","unstructured":"Wang D, Gao Y, Yun L: Study on brain targeting of raltitrexed following intranasal administration in rats. Cancer Chemother Pharmacol. 2006, 57: 97-104. 10.1007\/s00280-005-0018-3.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1003_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0378-5173(00)00612-8","volume":"212","author":"M Dahlin","year":"2001","unstructured":"Dahlin M, Bjork E: Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats. Int J Pharm. 2001, 212: 267-274. 10.1016\/S0378-5173(00)00612-8.","journal-title":"Int J Pharm"},{"key":"1003_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/10611860310001640075","volume":"11","author":"MP Van den Berg","year":"2003","unstructured":"Berg Van den MP, Merkus P, Romeijn SG, Verhoef JC, Merkus FW: Hydroxocobalamin uptake into the cerebrospinal fluid after nasal and intravenous delivery in rats and humans. J Drug Target. 2003, 11: 325-331. 10.1080\/10611860310001640075.","journal-title":"J Drug Target"},{"key":"1003_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1023\/B:PHAM.0000026431.55383.69","volume":"21","author":"MP van den Berg","year":"2004","unstructured":"Berg van den MP, Merkus P, Romeijn SG, Verhoef JC, Merkus FW: Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study. Pharm Res. 2004, 21: 799-802. 10.1023\/B:PHAM.0000026431.55383.69.","journal-title":"Pharm Res"},{"key":"1003_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejpb.2004.02.010","volume":"58","author":"MP van den Berg","year":"2004","unstructured":"Berg van den MP, Verhoef JC, Romeijn SG, Merkus FW: Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm. 2004, 58: 131-135. 10.1016\/j.ejpb.2004.02.010.","journal-title":"Eur J Pharm Biopharm"},{"key":"1003_CR14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/jps.20334","volume":"94","author":"Z Yang","year":"2005","unstructured":"Yang Z, Huang Y, Gan G, Sawchuk RJ: Microdialysis evaluation of the brain distribution of stavudine following intranasal and intravenous administration to rats. J Pharm Sci. 2005, 94: 1577-1588. 10.1002\/jps.20334.","journal-title":"J Pharm Sci"},{"key":"1003_CR15","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1248\/cpb.39.2456","volume":"39","author":"T Sakane","year":"1991","unstructured":"Sakane T, Akizuki M, Yamashita S, Nadai T, Hashida M, Sezaki H: The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull (Tokyo). 1991, 39: 2456-2458.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"1003_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.2042-7158.1994.tb03817.x","volume":"46","author":"T Sakane","year":"1994","unstructured":"Sakane T, Akizuki M, Yamashita S, Sezaki H, Nadai T: Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug. J Pharm Pharmacol. 1994, 46: 378-379.","journal-title":"J Pharm Pharmacol"},{"key":"1003_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.2042-7158.1995.tb05814.x","volume":"47","author":"T Sakane","year":"1995","unstructured":"Sakane T, Akizuki M, Taki Y, Yamashita S, Sezaki H, Nadai T: Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J Pharm Pharmacol. 1995, 47: 379-381.","journal-title":"J Pharm Pharmacol"},{"key":"1003_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1124\/jpet.301.1.391","volume":"301","author":"L Illum","year":"2002","unstructured":"Illum L, Watts P, Fisher AN, Hinchcliffe M, Norbury H, Jabbal-Gill I, Nankervis R, Davis SS: Intranasal delivery of morphine. J Pharmacol Exp Ther. 2002, 301: 391-400. 10.1124\/jpet.301.1.391.","journal-title":"J Pharmacol Exp Ther"},{"key":"1003_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0378-5173(00)00668-2","volume":"213","author":"JC Olivier","year":"2001","unstructured":"Olivier JC, Djilani M, Fahmy S, Couet W: In situ nasal absorption of midazolam in rats. Int J Pharm. 2001, 213: 187-192. 10.1016\/S0378-5173(00)00668-2.","journal-title":"Int J Pharm"},{"key":"1003_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1023\/A:1007551927177","volume":"17","author":"S Ahmed","year":"2000","unstructured":"Ahmed S, Sileno AP, deMeireles JC, Dua R, Pimplaskar HK, Xia WJ, Marinaro J, Langenback E, Matos FJ, Putcha L, Romeo VD, Behl CR: Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm Res. 2000, 17: 974-977. 10.1023\/A:1007551927177.","journal-title":"Pharm Res"},{"key":"1003_CR21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/jps.2600800808","volume":"80","author":"MA Hussain","year":"1991","unstructured":"Hussain MA, Mollica JA: Intranasal absorption of physostigmine and arecoline. J Pharm Sci. 1991, 80: 750-751. 10.1002\/jps.2600800808.","journal-title":"J Pharm Sci"},{"key":"1003_CR22","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/jps.20389","volume":"94","author":"AK Leonard","year":"2005","unstructured":"Leonard AK, Sileno AP, MacEvilly C, Foerder CA, Quay SC, Costantino HR: Development of a novel high-concentration galantamine formulation suitable for intranasal delivery. J Pharm Sci. 2005, 94: 1736-1746. 10.1002\/jps.20389.","journal-title":"J Pharm Sci"},{"key":"1003_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijpharm.2006.11.013","volume":"335","author":"AK Leonard","year":"2007","unstructured":"Leonard AK, Sileno AP, Brandt GC, Foerder CA, Quay SC, Costantino HR: In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm. 2007, 335: 138-146. 10.1016\/j.ijpharm.2006.11.013.","journal-title":"Int J Pharm"},{"key":"1003_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/1567205054367838","volume":"2","author":"CG Ballard","year":"2005","unstructured":"Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S: Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res. 2005, 2: 307-318. 10.2174\/1567205054367838.","journal-title":"Curr Alzheimer Res"},{"key":"1003_CR25","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1093\/brain\/awl280","volume":"129","author":"HW Klafki","year":"2006","unstructured":"Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J: Therapeutic approaches to Alzheimer's disease. Brain. 2006, 129: 2840-2855. 10.1093\/brain\/awl280.","journal-title":"Brain"},{"key":"1003_CR26","first-page":"417","volume":"10","author":"DS Geldmacher","year":"2006","unstructured":"Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, Banerjee S, Lin P, Sano M: Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006, 10: 417-429.","journal-title":"J Nutr Health Aging"},{"key":"1003_CR27","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.4088\/JCP.v67n1118","volume":"67","author":"RJ Caselli","year":"2006","unstructured":"Caselli RJ, Beach TG, Yaari R, Reiman EM: Alzheimer's disease a century later. J Clin Psychiatry. 2006, 67: 1784-1800.","journal-title":"J Clin Psychiatry"},{"key":"1003_CR28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/106002809402800612","volume":"28","author":"ML Crismon","year":"1994","unstructured":"Crismon ML: Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother. 1994, 28: 744-751.","journal-title":"Ann Pharmacother"},{"key":"1003_CR29","doi-asserted-by":"publisher","first-page":"10254","DOI":"10.1124\/jpet.102.045773","volume":"305","author":"M Samochocki","year":"2003","unstructured":"Samochocki M, H\u00f6ffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque WX, Maelicke A: Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not muscarinic acetylcholine receptors. J Pharmacol Exp Ther. 2003, 305: 10254-1036. 10.1124\/jpet.102.045773.","journal-title":"J Pharmacol Exp Ther"},{"key":"1003_CR30","first-page":"334","volume":"21","author":"G Lou","year":"1996","unstructured":"Lou G, Montgomery PR, Sitar DS: Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease. J Psychiatry Neurosci. 1996, 21: 334-339.","journal-title":"J Psychiatry Neurosci"},{"key":"1003_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1021\/js970359u","volume":"87","author":"AV Gore","year":"1998","unstructured":"Gore AV, Liang AC, Chien YW: Comparative biomembrane permeation of tacrine using Yucatan minipigs and domestic pigs as the animal model. J Pharm Sci. 1998, 87: 441-447. 10.1021\/js970359u.","journal-title":"J Pharm Sci"},{"key":"1003_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2125.1995.tb04410.x","volume":"39","author":"K Walter","year":"1995","unstructured":"Walter K, Muller M, Barkworth MF, Nieciecki AV, Stanislaus F: Pharmacokinetics of physostigmine in man following a single application of a transdermal system. Br J Clin Pharmacol. 1995, 39: 59-63.","journal-title":"Br J Clin Pharmacol"},{"key":"1003_CR33","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1517\/13543784.9.10.2393","volume":"9","author":"JJ Sramek","year":"2000","unstructured":"Sramek JJ, Frackiewicz EJ, Cutler NR: Review of the acetylcholinesterase inhibitor galantamine. Expert Opin Investig Drugs. 2000, 9: 2393-2402. 10.1517\/13543784.9.10.2393.","journal-title":"Expert Opin Investig Drugs"},{"key":"1003_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejphar.2004.07.054","volume":"49","author":"VI Turiiski","year":"2004","unstructured":"Turiiski VI, Krustev AD, Sirakov VN, Getova DP: In vivo and in vitro study of the influence of the anticholinesterase drug galantamine on motor and evacuative functions of rat gastrointestinal tract. Eur J Pharmacol. 2004, 49: 233-239. 10.1016\/j.ejphar.2004.07.054.","journal-title":"Eur J Pharmacol"},{"key":"1003_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/17425247.2.2.281","volume":"2","author":"PH Johnson","year":"2005","unstructured":"Johnson PH, Quay SC: Advances in nasal drug delivery through tight junction technology. Expert Opin Drug Deliv. 2005, 2: 281-98. 10.1517\/17425247.2.2.281.","journal-title":"Expert Opin Drug Deliv"},{"key":"1003_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2131\/jts.22.5_409","volume":"22","author":"M Yamashita","year":"1997","unstructured":"Yamashita M, Yamashita M, Tanaka J, Chagi K, Takeda S, Kurihara T, Takeda Y, Fujii Y: Vomiting induction by ipecac syrup in dogs and ferrets. J Toxicol Sci. 1997, 22: 409-412.","journal-title":"J Toxicol Sci"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2202-9-S3-S6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2202-9-S3-S6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2202-9-S3-S6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T18:58:13Z","timestamp":1548183493000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/1471-2202-9-S3-S6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":36,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1186\/1471-2202-9-s3-s6","relation":{},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]},"article-number":"S6"}}